Dose proportionality and bioavailability of quinoxaline-based JNK inhibitor after single oral and intravenous administration in rats

References

• Azman M, Sabri AH, Anjani QK, Mustaffa MF, Hamid KA. 2022. Intestinal absorption study: challenges and absorption enhancement strategies in improving oral drug delivery. Pharmaceuticals (Basel). 15(8):975. doi:10.3390/ph15080975.
   PubMedGoogle Scholar
• Back DJ, Madden S, Orme ML. 1990. Gastrointestinal metabolism of contraceptive steroids. Am J Obstet Gynecol. 163(6):2138–2145. doi:10.1016/0002-9378(90)90554-k.
   PubMed Web of Science ®Google Scholar
• Cicenas J. 2015. JNK inhibitors: is there a future? MAP Kinase. 4(1):32–35. doi:10.4081/mk.2015.5700.
   Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095. doi:10.1023/a:1018943613122.
   PubMed Web of Science ®Google Scholar
• [EMA] European Medicines Agency. 2011. Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. London (UK); [accessed 2015 Jun 3]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.
   Google Scholar
• [EMEA] European Agency for Evaluation of Medicinal Products 2000. Committee for Proprietary Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London (UK); [accessed 2000 Dec 14]. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-investigation-bioavailability-bioequivalence_en.pdf.
   Google Scholar
• European Parliament and the Council of the European Union. 2010. Directive 2010/63/EU on the protection of animals used for scientific purposes. OJEC. L. 276:33–79. [accessed 2010 Sept 22]. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32010L0063.
   Google Scholar
• [FDA] Food and Drug Administration. 2022. Center for Drug Evaluation and Research (CDER). Bioavailability Studies Submitted in NDAs or INDs - General Considerations. Rockville (MD); [accessed 2022 Apr 14]. https://www.fda.gov/files/drugs/published/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf.
   Google Scholar
• Ghadi R, Dand N. 2017. BCS class IV drugs: highly notorious candidates for formulation development. J Control Release. 248:71–95. doi:10.1016/j.jconrel.2017.01.014.
   PubMed Web of Science ®Google Scholar
• Gough K, Hutchison M, Keene ON, Byrom B, Ellis S, Lacey LF, McKellar JW. 1995. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf. J. 29(3):1039–1048. doi:10.1177/009286159502900324.
   Google Scholar
• Hummel J, McKendrick S, Brindley C, French R. 2009. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 8(1):38–49. doi:10.1002/pst.326.
   PubMed Web of Science ®Google Scholar
• Kirpotina LN, Schepetkin IA, Hammaker D, Kuhs A, Khlebnikov AI, Quinn MT. 2020. Therapeutic effects of tryptanthrin and tryptanthrin-6-oxime in models of rheumatoid arthritis. Front Pharmacol. 11:1145. doi:10.3389/fphar.2020.01145.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh UK, Kini SG, Garg V, Agrawal S, Tomar PK, Pathak P, Chaudhary A, Malik PA, Malik PG. 2015. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem. 7(15):2065–2086. doi:10.4155/fmc.15.132.
   PubMed Web of Science ®Google Scholar
• Kyriakis JM, Avruch J. 2012. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 92(2):689–737. doi:10.1152/physrev.00028.2011.
   PubMed Web of Science ®Google Scholar
• Laffleur F, Keckeis V. 2020. Advances in drug delivery systems: work in progress still needed? Int J Pharm X. 2:100050. doi:10.1016/j.ijpx.2020.100050.
   PubMedGoogle Scholar
• Lakeev AP, Frelikh GA, Yanovskaya EA, Kovrizhina AR, Udut VV. 2022. Quantification of a promising JNK inhibitor and nitrovasodilator IQ-1 and its major metabolite in rat plasma by LC-MS/MS. Bioanalysis. 14(22):1423–1441. doi:10.4155/bio-2022-0193.
   PubMed Web of Science ®Google Scholar
• Matveevskaya VV, Pavlov DI, Kovrizhina AR, Sukhikh TS, Sadykov EH, Dorovatovskii PV, Lazarenko VA, Khlebnikov AI, Potapov AS. 2023. Experimental and computational investigation of the oxime bond stereochemistry in c-Jun N-terminal kinase 3 inhibitors 11H-Indeno[1,2-b]quinoxalin-11-one oxime and tryptanthrin-6-oxime. Pharmaceutics. 15(7):1802. doi:10.3390/pharmaceutics15071802.
   PubMed Web of Science ®Google Scholar
• Musi CA, Agrò G, Santarella F, Iervasi E, Borsello T. 2020. JNK3 as therapeutic target and biomarker in neurodegenerative and neurodevelopmental brain diseases. Cells. 9(10):2190. doi:10.3390/cells9102190.
   PubMed Web of Science ®Google Scholar
• Ozawa T, Takayama K, Okamoto R, Negoro R, Sakurai F, Tachibana M, Kawabata K, Mizuguchi H. 2015. Generation of enterocyte-like cells from human induced pluripotent stem cells for drug absorption and metabolism studies in human small intestine. Sci Rep. 5(1):16479. doi:10.1038/srep16479.
   PubMedGoogle Scholar
• Pant A, Maiti TK, Mahajan D, Das B. 2023. Gut microbiota and drug metabolism. Microb Ecol. 86(1):97–111. doi:10.1007/s00248-022-02081-x.
   PubMed Web of Science ®Google Scholar
• Plotnikov MB, Chernysheva GA, Smolyakova VI, Aliev OI, Trofimova ES, Sherstoboev EY, Osipenko AN, Khlebnikov AI, Anfinogenova YJ, Schepetkin IA, et al. 2020. Neuroprotective effects of a novel inhibitor of c-Jun N-terminal kinase in the rat model of transient focal cerebral ischemia. Cells. 9(8):1860. doi:10.3390/cells9081860.
   PubMed Web of Science ®Google Scholar
• Popmihajlov Z, Sutherland DJ, Horan GS, Ghosh A, Lynch DA, Noble PW, Richeldi L, Reiss TF, Greenberg S. 2022. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respir Res. 9(1):e001060. doi:10.1136/bmjresp-2021-001060.
   PubMed Web of Science ®Google Scholar
• Rehfeldt SCH, Majolo F, Goettert MI, Laufer S. 2020. c-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer’s diseases. IJMS. 21(24):9677. doi:10.3390/ijms21249677.
   Google Scholar
• Schepetkin IA, Chernysheva GA, Aliev OI, Kirpotina LN, Smol’yakova VI, Osipenko AN, Plotnikov MB, Kovrizhina AR, Khlebnikov AI, Plotnikov EV, et al. 2022. Neuroprotective effects of the lithium salt of a novel JNK inhibitor in an animal model of cerebral ischemia–reperfusion. Biomedicines. 10(9):2119. doi:10.3390/biomedicines10092119.
   PubMed Web of Science ®Google Scholar
• Schepetkin IA, Khlebnikov AI, Potapov AS, Kovrizhina AR, Matveevskaya VV, Belyanin ML, Atochin DN, Zanoza SO, Gaidarzhy NM, Lyakhov SA, et al. 2019. Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors. Eur J Med Chem.161:179–191. doi:10.1016/j.ejmech.2018.10.023.
   PubMed Web of Science ®Google Scholar
• Schepetkin IA, Kirpotina LN, Hammaker D, Kochetkova I, Khlebnikov AI, Lyakhov SA, Firestein GS, Quinn MT. 2015. Anti-inflammatory effects and joint protection in collagen-induced arthritis after treatment with IQ-1S, a selective c-Jun N-terminal kinase inhibitor. J Pharmacol Exp Ther. 353(3):505–516. doi:10.1124/jpet.114.220251.
   PubMed Web of Science ®Google Scholar
• Shvedova M, Anfinogenova Y, Atochina-Vasserman EN, Schepetkin IA, Atochin DN. 2018. c-Jun N-terminal kinases (JNKs) in myocardial and cerebral ischemia/reperfusion injury. Front Pharmacol. 9:715. doi:10.3389/fphar.2018.00715.
   PubMed Web of Science ®Google Scholar
• Testa B, Krämer SD. 2007. The biochemistry of drug metabolism – an introduction: part 3. reactions of hydrolysis and their enzymes. Chem Biodivers. 4(9):2031–2122. doi:10.1002/cbdv.200790169.
   PubMed Web of Science ®Google Scholar
• Wang J, Li G, Rui T, Kang A, Li G, Fu T, Li J, Di L, Cai B. 2017. Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality. RSC Adv. 7(15):9057–9063. doi:10.1039/C6RA28237G.
   Web of Science ®Google Scholar
• Yang Y, Zhao Y, Yu A, Sun D, Yu LX. 2016. Oral drug absorption: evaluation and prediction. In: Qiu Y, Chen Y, Zhang GGZ, Yu L, Mantri RV, editors. Developing solid oral dosage forms. 2nd ed. Cambridge (MA): Academic Press; p. 331–354. doi:10.1016/B978-0-12-802447-8.00012-1.
   Google Scholar